Erbitux Solution
NDC Package 66733-948-23
Package Information
Erbitux (cetuximab) solution is cetuximab is used to treat a certain type of cancer of the colon (large intestine) or rectum. This formulation utilizes a solution delivery system. Marketed by Imclone Llc, this product is identified by NDC 66733-948 and is authorized under FDA application BLA125084.
Identification & Billing
- RxCUI: 1657658 - cetuximab 100 MG in 50 ML Injection
- RxCUI: 1657658 - 50 ML cetuximab 2 MG/ML Injection
- RxCUI: 1657658 - cetuximab 100 MG per 50 ML Injection
- RxCUI: 1657660 - Erbitux 100 MG in 50 ML Injection
- RxCUI: 1657660 - 50 ML cetuximab 2 MG/ML Injection [Erbitux]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 66733 - Imclone Llc
- 66733-948 - Erbitux
- 66733-948-23 - 1 VIAL, SINGLE-DOSE in 1 CARTON / 50 mL in 1 VIAL, SINGLE-DOSE
- 66733-948 - Erbitux
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 66733-948-23 identifies a specific commercial package of 1 vial, single-dose in 1 carton / 50 ml in 1 vial, single-dose of Erbitux, a human prescription drug labeled by Imclone Llc. This solution is formulated for intravenous use and contains cetuximab as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Imclone Llc on February 12, 2004. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
Cetuximab is used to treat a certain type of cancer of the colon (large intestine) or rectum. This medication is also used to treat head and neck cancer. Cetuximab works by slowing or stopping the growth of cancer cells. It binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors. Cetuximab is a man-made protein (monoclonal antibody).
How is this Imclone Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 66733094823. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
